Brokerages Set Celldex Therapeutics, Inc. (NASDAQ:CLDX) Target Price at $62.25

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) have received an average recommendation of “Moderate Buy” from the nine brokerages that are currently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $62.25.

A number of analysts have recently weighed in on CLDX shares. Wolfe Research lowered shares of Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research note on Friday, September 27th. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price target on shares of Celldex Therapeutics in a research report on Wednesday, November 20th. The Goldman Sachs Group initiated coverage on Celldex Therapeutics in a report on Monday, September 30th. They issued a “neutral” rating and a $45.00 price objective for the company. Wells Fargo & Company raised Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 26th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $67.00 price target on shares of Celldex Therapeutics in a report on Monday, September 16th.

Celldex Therapeutics Trading Down 1.4 %

Shares of NASDAQ:CLDX opened at $26.40 on Tuesday. Celldex Therapeutics has a twelve month low of $22.93 and a twelve month high of $53.18. The company has a market cap of $1.75 billion, a PE ratio of -10.27 and a beta of 1.57. The company’s 50 day moving average is $27.65 and its 200 day moving average is $33.90.

Insider Activity at Celldex Therapeutics

In other news, CEO Anthony S. Marucci acquired 11,500 shares of the firm’s stock in a transaction on Monday, November 11th. The shares were bought at an average price of $26.82 per share, for a total transaction of $308,430.00. Following the acquisition, the chief executive officer now owns 40,284 shares of the company’s stock, valued at approximately $1,080,416.88. This trade represents a 39.95 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 3.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Celldex Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Celldex Therapeutics in the 2nd quarter valued at about $76,000. KBC Group NV grew its position in shares of Celldex Therapeutics by 31.2% in the third quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 495 shares in the last quarter. CANADA LIFE ASSURANCE Co increased its holdings in shares of Celldex Therapeutics by 26.4% in the first quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock valued at $192,000 after purchasing an additional 955 shares during the last quarter. Los Angeles Capital Management LLC lifted its position in Celldex Therapeutics by 9.5% during the second quarter. Los Angeles Capital Management LLC now owns 7,371 shares of the biopharmaceutical company’s stock worth $273,000 after buying an additional 638 shares in the last quarter. Finally, Quest Partners LLC boosted its stake in Celldex Therapeutics by 1,364.9% during the second quarter. Quest Partners LLC now owns 7,383 shares of the biopharmaceutical company’s stock worth $273,000 after buying an additional 6,879 shares during the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.